ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 79 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,708,597 | -44.3% | 510,094 | +0.0% | 0.00% | -50.0% |
| Q2 2023 | $4,859,151 | -12.9% | 509,879 | +0.4% | 0.00% | 0.0% |
| Q1 2023 | $5,577,846 | -35.1% | 508,019 | -12.5% | 0.00% | -42.9% |
| Q4 2022 | $8,597,157 | -22.8% | 580,889 | -0.4% | 0.01% | -30.0% |
| Q3 2022 | $11,140,000 | -7.4% | 582,936 | +3.2% | 0.01% | 0.0% |
| Q2 2022 | $12,032,000 | +19.1% | 564,644 | +7.6% | 0.01% | +42.9% |
| Q1 2022 | $10,103,000 | +0.0% | 524,559 | +7.7% | 0.01% | +16.7% |
| Q4 2021 | $10,102,000 | +12.4% | 487,071 | +29.5% | 0.01% | 0.0% |
| Q3 2021 | $8,985,000 | -12.6% | 376,074 | -0.1% | 0.01% | -14.3% |
| Q2 2021 | $10,278,000 | -5.5% | 376,620 | +0.2% | 0.01% | -12.5% |
| Q1 2021 | $10,872,000 | +34.1% | 375,796 | +30.3% | 0.01% | +33.3% |
| Q4 2020 | $8,110,000 | – | 288,300 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 8,684,232 | $165,956,000 | 12.78% |
| Bain Capital Life Sciences Investors, LLC | 3,000,000 | $57,330,000 | 6.84% |
| Pivotal bioVenture Partners Investment Advisor LLC | 569,041 | $10,874,000 | 3.97% |
| Logos Global Management LP | 1,525,000 | $29,143,000 | 3.58% |
| 1492 Capital Management LLC | 178,320 | $3,408,000 | 2.45% |
| Cormorant Asset Management, LP | 1,000,000 | $19,110,000 | 1.34% |
| MPM BioImpact LLC | 257,185 | $4,915,000 | 1.16% |
| Orbimed Advisors | 2,800,000 | $53,508,000 | 0.99% |
| SECTORAL ASSET MANAGEMENT INC | 220,985 | $4,223,000 | 0.83% |
| Rubric Capital Management LP | 472,047 | $9,021,000 | 0.45% |